88 related articles for article (PubMed ID: 21566576)
1. Breaking immunological tolerance to melanocyte differentiation antigens by hypopigmenting agents: a new means for melanoma immunotherapy?
Becker JC; Schrama D
J Invest Dermatol; 2011 Jun; 131(6):1185-7. PubMed ID: 21566576
[TBL] [Abstract][Full Text] [Related]
2. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.
van den Boorn JG; Picavet DI; van Swieten PF; van Veen HA; Konijnenberg D; van Veelen PA; van Capel T; Jong EC; Reits EA; Drijfhout JW; Bos JD; Melief CJ; Luiten RM
J Invest Dermatol; 2011 Jun; 131(6):1240-51. PubMed ID: 21326294
[TBL] [Abstract][Full Text] [Related]
3. Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.
Bonchak JG; Eby JM; Willenborg KA; Chrobak D; Henning SW; Krzywiec A; Johnson SL; Le Poole IC
Arch Biochem Biophys; 2014 Dec; 563():71-8. PubMed ID: 25132642
[TBL] [Abstract][Full Text] [Related]
4. Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation.
Hariharan V; Klarquist J; Reust MJ; Koshoffer A; McKee MD; Boissy RE; Le Poole IC
J Invest Dermatol; 2010 Jan; 130(1):211-20. PubMed ID: 19657355
[TBL] [Abstract][Full Text] [Related]
5. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity.
van den Boorn JG; Melief CJ; Luiten RM
Pigment Cell Melanoma Res; 2011 Aug; 24(4):673-9. PubMed ID: 21689385
[TBL] [Abstract][Full Text] [Related]
6. Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.
Webb KC; Eby JM; Hariharan V; Hernandez C; Luiten RM; Le Poole IC
Exp Dermatol; 2014 Aug; 23(8):529-33. PubMed ID: 24840876
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin.
Kasraee B; Fallahi MR; Ardekani GS; Ebrahimi S; Doroudchi G; Omrani GR; Handjani F; Amini M; Tanideh N; Haddadi M; Nikbakhsh M; Jahanbani S; Tran C; Sorg O; Saurat JH
Exp Dermatol; 2006 Jul; 15(7):509-14. PubMed ID: 16761959
[TBL] [Abstract][Full Text] [Related]
8. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.
Speeckaert R; van Geel N; Vermaelen KV; Lambert J; Van Gele M; Speeckaert MM; Brochez L
Pigment Cell Melanoma Res; 2011 Apr; 24(2):334-44. PubMed ID: 21029398
[TBL] [Abstract][Full Text] [Related]
9. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.
van den Boorn JG; Konijnenberg D; Tjin EP; Picavet DI; Meeuwenoord NJ; Filippov DV; van der Veen JP; Bos JD; Melief CJ; Luiten RM
PLoS One; 2010 May; 5(5):e10626. PubMed ID: 20498710
[TBL] [Abstract][Full Text] [Related]
10. The histological and immunohistochemical changes in the skin of patients with melanoma who develop changes in skin pigmentation following immunotherapy.
Salter J; MacLennan K; Bridgewater JA; Moore J; Atkinson H; Nicolson M; Riches P; Gore ME
Melanoma Res; 1995 Aug; 5(4):267-71. PubMed ID: 7496163
[TBL] [Abstract][Full Text] [Related]
11. A mouse model of vitiligo induced by monobenzone.
Zhu Y; Wang S; Xu A
Exp Dermatol; 2013 Jul; 22(7):499-501. PubMed ID: 23800067
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ
Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic effects of EGCG on vitiligo.
Zhu Y; Wang S; Lin F; Li Q; Xu A
Fitoterapia; 2014 Dec; 99():243-51. PubMed ID: 25128425
[TBL] [Abstract][Full Text] [Related]
14. Depigmenting action of phenylhydroquinone, an O-phenylphenol metabolite, on the skin of JY-4 black guinea-pigs.
Tayama K; Takahama M
Pigment Cell Res; 2002 Dec; 15(6):447-53. PubMed ID: 12453187
[TBL] [Abstract][Full Text] [Related]
15. [The mechanism of depigmentation by hydroquinone: a study on suppression and recovery processes of tyrosinase activity in the pigment cells in vivo and in vitro].
Hashimoto A; Ichihashi M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1984 Jun; 94(7):797-804. PubMed ID: 6436557
[No Abstract] [Full Text] [Related]
16. Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis.
Teulings HE; Tjin EP; Willemsen KJ; Krebbers G; van Noesel CJ; Kemp EH; Nieuweboer-Krobotova L; van der Veen JP; Luiten RM
Br J Dermatol; 2013 Apr; 168(4):733-8. PubMed ID: 23421690
[TBL] [Abstract][Full Text] [Related]
17. Depigmenting action of hydroquinone depends on disruption of fundamental cell processes.
Penney KB; Smith CJ; Allen JC
J Invest Dermatol; 1984 Apr; 82(4):308-10. PubMed ID: 6200545
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression and melanocyte proliferation.
Zattra E; Fortina AB; Bordignon M; Piaserico S; Alaibac M
Melanoma Res; 2009 Apr; 19(2):63-8. PubMed ID: 19194340
[TBL] [Abstract][Full Text] [Related]
19. Depigmentation therapies for normal skin in vitiligo universalis.
AlGhamdi KM; Kumar A
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):749-57. PubMed ID: 21054565
[TBL] [Abstract][Full Text] [Related]
20. Dermatitis produced by applications of monobenzone in patients with active vitiligo.
Nordlund JJ; Forget B; Kirkwood J; Lerner AB
Arch Dermatol; 1985 Sep; 121(9):1141-4. PubMed ID: 2931053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
